snow
Events - Slide 1 Events - Slide 2 Events - Slide 3 Events - Slide 4

Welcome to Retina Specialists Northwest

Dedicated to delivering compassionate excellence in retinal and inflammatory eye disease always.

Retina Specialists Northwest, PLLC is an ophthalmic subspecialty practice focused on Retina and Uveitis. The practice philosophy is summarized in the company motto: Compassionate Excellence Always.

Board certified eye physician and surgeon, Dr. Brenda Myers-Powell

Dr. Myers-Powell and her staff are committed to delivering the best in personalized retinal care efficiently and effectively. Our pledge is to understand you as a whole and to provide the best available medical and surgical treatment tailored to your needs. We are centrally located between Seattle and Tacoma, at West Campus in Federal Way, strategically positioned to deliver quality care to residents within and outside the metropolitan areas. Our office is easily accessible from I-5, Hwy-18, Hwy-167, and Hwy-99. For your convenience, we are open most Saturdays.

We utilize the latest technology as well as clinical expertise to diagnose and manage all retinal and inflammatory disorders with particular attention to Retinal Tear and Detachment, Disorders of the Vitreous, Macular Holes, Diabetic Retinopathy, Age-related Macular Degeneration, Retinal Vascular Disease, Macular Edema, Scleritis, and vision-threatening Uveitis.

Ultra-Widefield Multifocal Electroretinography and Visual Evoked Potentials

Retina Specialists Northwest is proud to announce the implementation of Diagnosys Ultra-Widefield Multifocal Electroretinography (mfERG) and Visual Evoked Potentials (VEP) as part of our service. This diagnostic tool can significantly benefit those with retinal and optic nerve disease.

Retina Specialists Northwest has invested in elevating the level of care in the Puget Sound area by providing a valuable service that had previously been unavailable in our community.

The mfERG can objectively assess cone dysfunction and macular disease facilitating diagnosis and assessment of progression of macular disorders such as Retinal Dystrophy, ARMD, Diabetic Retinopathy and Drug Toxicity. The AAO has listed mfERG as a critical test modality for screening for Plaquenil Toxicity.

VEP can assess optic nerve function, improving the diagnosis and management of Optic Neuritis and Optic Neuropathy. This is particularly useful in Multiple Sclerosis.

Our Federal Way office will provide this service at your patients' convenience.

Call (253) 517-3334 to schedule an appointment.

News from NEI

NIH Vision Scientists Test Theory of How Rods in our Retina Originated

Retinas from our earliest vertebrate ancestors had cone-like photoreceptors, presumably allowing them to see in daylight, but little ability to see at night. Then, millions of years ago in the Mesozoic era, and in relatively short order, mammals emerged that had retinas with predominantly rod photoreceptors, allowing for them to see at night perhaps to hunt for food while their dinosaur predators were dozing. Now a new study led by researchers the National Eye Institute suggests how the genesis of rod photoreceptors may have occurred to give rise to nocturnal mammals.

06/20/16 10:27 am

NEI Welcomes Four New Members to National Advisory Eye Council

Today four new members join the National Advisory Eye Council, an advisory body for the National Eye Institute (NEI) at NIH. The council provides advice to guide NEI research and training programs.

“NEI welcomes these new appointees; the breadth of their expertise will be invaluable,” said NEI director Paul A. Sieving, M.D., Ph.D. “We look forward to receiving their guidance as we continue to advance vision research, translating discoveries into treatments and therapies for patients.”

The four new council members are:




English

06/15/16 10:34 am

Eye Study Underscores the Long-lasting Benefits of Controlling Diabetes

People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy. Investigators who led the ACCORD Follow-on Eye Study (ACCORDION) announced the results today in New Orleans at the American Diabetes Association annual meeting. The study was supported by the National Institutes of Health’s National Eye Institute (NEI).

English

06/10/16 8:15 am

Visual impairment, blindness cases in U.S. expected to double by 2050

With the youngest of the baby boomers hitting 65 by 2029, the number of people with visual impairment or blindness in the United States is expected to double to more than 8 million by 2050, according to projections based on the most recent census data and from studies funded by the National Eye Institute, part of the National Institutes of Health. Another 16.4 million Americans are expected to have difficulty seeing due to correctable refractive errors such as myopia (nearsightedness) or hyperopia (farsightedness) that can be fixed with glasses, contacts or surgery.

English

05/18/16 12:07 pm

Age-related macular degeneration before and after the era of anti-VEGF drugs

In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs’ availability.

English

05/02/16 7:10 am